Details of the Drug

General Information of Drug (ID: DM2O8VW)

Drug Name

Eclitasertib

Synonyms

Eclitasertib; 2125450-76-0; DNL758; Eclitasertib [INN]; Eclitasertib [USAN]; SAR443122; DNL-758; 975AT1P9J6; Eclitasertib [USAN:INN]; UNII-975AT1P9J6; WHO 11844; SAR-443122; 3-(Phenylmethyl)-N-((3S)-2,3,4,5-tetrahydro-5-methyl-4-oxopyrido(3,2-b)(1,4)oxazepin-3-yl)-1H-1,2,4-triazole-5-carboxamide; 1H-1,2,4-Triazole-5-carboxamide, 3-(phenylmethyl)-N-((3S)-2,3,4,5-tetrahydro-5-methyl-4-oxopyrido(3,2-b)(1,4)oxazepin-3-yl)-; 5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydropyrido[3,2-b][1,4]oxazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide; ECLITASERTIB [WHO-DD]; CHEMBL4861471; SCHEMBL19207477; GTPL11308; US9815850, Compound 42; BDBM356271; EX-A5731; US9815850, Compound 169; AKOS040759938; AT37390; DNL-758; SAR-443122; example 42 [WO2017136727A2]; MS-26168; HY-114371; CS-0084281

Indication

Disease Entry	ICD 11	Status	REF
Ulcerative colitis	DD71	Phase 2	[1]

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C19H18N6O3
Canonical SMILES: CN1C(=O)C(COC2=C1N=CC=C2)NC(=O)C3=NNC(=N3)CC4=CC=CC=C4
InChI: InChI=1S/C19H18N6O3/c1-25-17-14(8-5-9-20-17)28-11-13(19(25)27)21-18(26)16-22-15(23-24-16)10-12-6-3-2-4-7-12/h2-9,13H,10-11H2,1H3,(H,21,26)(H,22,23,24)/t13-/m0/s1
InChIKey: XUZICJHIIJCKQQ-ZDUSSCGKSA-N

Cross-matching ID

PubChem CID: 130298939
ChEBI ID: CHEMBL4861471
TTD ID: DWM2Y5

Drug-Molecule Activity Atlas (DMA)^NEW

Click to Jump to the Detailed DMA Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Receptor-interacting protein 1 (RIPK1)	TTAIQSN	RIPK1_HUMAN	Inhibitor	[2]

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05588843) A Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Assess the Efficacy and Safety of SAR443122 in Adult Patients With Moderate to Severe Ulcerative Colitis. U.S.National Institutes of Health.
2	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight